GUARDANT HEALTH PTE LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations 2024-08-30 11:01
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa 2024-01-08 15:30
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea 2023-11-13 08:00
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers 2023-05-30 09:00
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China 2022-07-06 18:17
Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan 2022-03-14 16:22
Guardant360 CDx submitted for regulatory approval in Japan 2021-02-03 18:41
First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health's Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa. 2020-08-08 03:21
Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients 2020-05-30 19:00
Guardant Health AMEA wins this year's Growth Excellence Leadership Award by Frost & Sullivan 2019-11-22 15:37
1